Invention Grant
- Patent Title: Ophthalmic drug sustained release formulation and uses thereof
-
Application No.: US16833883Application Date: 2020-03-30
-
Publication No.: US11324693B2Publication Date: 2022-05-10
- Inventor: Deepank Utkhede , Catherine Jones , David Wiseman
- Applicant: MATI THERAPEUTICS INC.
- Applicant Address: US TX Austin
- Assignee: MATI THERAPEUTICS INC.
- Current Assignee: MATI THERAPEUTICS INC.
- Current Assignee Address: US TX Austin
- Agency: Mati Therapeutics Inc.
- Agent Koren Anderson
- Main IPC: A61F9/00
- IPC: A61F9/00 ; A61F9/007 ; A61K31/165 ; A61K31/569 ; A61K31/573 ; A61K9/00 ; A61K47/34 ; A61K38/13 ; A61K47/10 ; A61K9/14

Abstract:
A solid matrix sustained release ophthalmic formulation for topical delivery of a solid ophthalmic drug to the eye, medical devices, drug cores, drug inserts and drug delivery systems comprising the formulation, methods of manufacturing the formulation, medical devices and their methods thereof for delivering the ophthalmic drug for a treatment period provided herein. The formulation disclosed herein is an admixture of an ophthalmic drug, and a combination of a hydrophobic polymer, a hydrophilic polymer and a surfactant, wherein the drug is eluted daily over an extended period of time at therapeutic dose of drug.
Public/Granted literature
- US20200222317A1 OPHTHALMIC DRUG SUSTAINED RELEASE FORMULATION AND USES THEREOF Public/Granted day:2020-07-16
Information query